Form 4: MapLight Therapeutics Officer Sells Shares for Tax

MapLight Therapeutics' CAAO and PAO, Jonathan Gillis, disposed of 22,050 shares of common stock to cover tax obligations related to restricted stock unit awards.

Summary

• Jonathan Gillis, the Chief Accounting and Administrative Officer (CAAO) and Principal Accounting Officer (PAO) of MapLight Therapeutics, Inc., reported a transaction.
• On January 27, 2026, Gillis disposed of 22,050 shares of Voting Common Stock.
• The disposition was a 'F' transaction code, indicating shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock unit awards.
• The shares were valued at $17.98 per share for the purpose of the transaction.
• Following this transaction, Gillis beneficially owns 248,503 shares of Voting Common Stock directly.
• The retained securities remain subject to a 180-day lock-up agreement from the initial public offering's final prospectus date of October 26, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transaction is a routine tax-related disposition of shares following the vesting of restricted stock units and does not indicate a change in the company's fundamentals or management's confidence.

Risks

• The reporting person's retained securities are subject to a lock-up agreement, restricting direct or indirect sale or transfer for 180 days following the final prospectus date of October 26, 2025.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the existing lock-up agreement for the reporting person's shares.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to tax withholdings upon RSU vesting, are common occurrences in the biotechnology and pharmaceutical sectors. These transactions typically do not reflect a change in management's outlook on the company's prospects but rather a routine administrative event.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary sale for tax purposes by an insider, not indicative of a change in company value or outlook.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by an insider to cover tax obligations upon the vesting of restricted stock units. Such transactions are common and generally do not reflect a change in the company's fundamental value or the insider's confidence. Therefore, it provides no new information that would warrant a change in investment recommendation, suggesting a 'hold' position based solely on this filing.

Keywords

MapLight Therapeutics, MPLT, Jonathan Gillis, Insider Transaction, Form 4, Tax Withholding, Restricted Stock Units, Common Stock, Lock-up Agreement